)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dynavax Technologies
Dynavax Technologies (DVAX) investor relations material
Dynavax Technologies has been acquired by Sanofi
Dynavax Technologies Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary2 Dec, 2025
Hepatitis B vaccine market strategy and trends
Targeting 60% market share of a $900M+ market by 2030, with current progress tracking well toward this goal.
Retail segment is key, already holding 63% share, with expectations to exceed 75% as more adult vaccinations shift to retail by 2030.
Growth in retail driven by post-pandemic changes: increased patient comfort, expanded pharmacist authority, and retail infrastructure.
Medicare patients (25% of pharmacy market) present further opportunity as reimbursement improves, aiming to capture more of this segment.
Seasonality patterns are evolving, with retail settings leveraging flu season to increase non-flu vaccine uptake.
COVID vaccine acquisition and development outlook
Recent acquisition of an oral COVID vaccine aims for a differentiated product with a novel mucosal delivery mechanism.
Market focus is on high-risk populations, with current COVID vaccine uptake down 15% year-over-year but still a multi-billion-dollar opportunity.
Deal structure allows for data review before major investment, balancing risk and capital deployment.
Advancement to Phase 3 and commercialization depends on efficacy data and regulatory clarity, with financial capacity to support development.
Efficacy trials will focus on symptomatic infection, with supportive endpoints like hospitalization and severity.
Shingles vaccine and global market potential
U.S. market will focus on the aging cohort and those dissatisfied with current options, with ex-U.S. prevalence market remaining large.
Potential for a booster market as age recommendations lower and vaccine efficacy wanes over time.
Commercialization strategy centers on retail pharmacy, leveraging existing infrastructure for synergy.
Flexible on ex-U.S. partnerships but aims to retain U.S. launch control, targeting early 2030s for market entry.
Upcoming Part 2 study will focus on vaccine response rate in 70+ age group, with supportive T cell and antibody data.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dynavax Technologies
- HEPLISAV-B's retail dominance and pipeline advances fuel growth, supported by disciplined strategy.DVAX
Wells Fargo 20th Annual Healthcare Conference 2025 - Targeting 60% market share and $900M revenue by 2030, with strong pipeline and capital returns.DVAX7th Annual Evercore ISI HealthCONx Healthcare Conference
- HEPLISAV-B sales up 24% in Q2 2024, with strong profit, liquidity, and pipeline progress.DVAXQ2 2024
- HEPLISAV-B's strong growth led to record Q3 results, positive outlook, and a $200M buyback.DVAXQ3 2024
- Hepatitis B vaccine leads growth and profitability, with pipeline advances in shingles, Tdap, and plague.DVAXGoldman Sachs 45th Annual Global Healthcare Conference
- HEPLISAV-B's growth and pipeline advances support leadership in adult vaccines.DVAXThe 44th Annual William Blair Growth Stock Conference
- Poised for transformational growth in 2025, driven by vaccine market expansion and pipeline advances.DVAXBarclays 27th Annual Global Healthcare Conference
- Heplisav-B growth, pipeline advances, and disciplined capital strategy drive long-term value.DVAXTD Cowen 45th Annual Healthcare Conference
- Record HEPLISAV-B growth, strong outlook, and pipeline milestones support continued expansion.DVAXQ4 2024
Dynavax Technologies
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dynavax Technologies Corporation is a biopharmaceutical company that develops and commercializes novel vaccines and immunotherapies. The company focuses on leveraging its proprietary Toll-like Receptor (TLR) immune modulation technology to enhance the efficacy of its products. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.